Menu
Svensk version

About BONESUPPORT

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for its gentamicin eluting product is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information.

BONESUPPORTTM and CERAMENT® are registered trademarks.

 

For more information contact:

BONESUPPORT AB

Emil Billbäck, CEO

+46 (0) 46 286 53 70

Håkan Johansson, CFO

+46(0) 46 286 53 70

ir@bonesupport.com

 

Cord Communications
Charlotte Stjerngren
+46 (0)708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

 

If you would like more information about BONESUPPORT or are interested in investing in the company, please contact:

INVESTOR RELATIONS

HÅKAN JOHANSSON

CHIEF FINANCIAL OFFICER

ir@bonesupport.com

T: +46 46 286 53 70

DO YOU WANT TO BE UPDATED ON ALL THE LATEST BONESUPPORT NEWS & EVENTS?

Please kindly fill in the form below and submit.

Press releases Product/events information
Yes, I would like to receive newsletters from BONESUPPORT and consent to the processing of my personal data for this purpose, as further described in the privacy policy.